Listen to this story. Enjoy more audio and podcasts on iOS or Android.
Your browser does not support the element.
AROUND THE world, dealmaking is in a rut. A combination of higher interest rates, geopolitical tensions and economic uncertainty has put a hold on joint ventures, mergers and acquisitions. One exception is targets with AI in their name. Another, less obvious one, involves a less catchy initialism: ADCs.
Makers of these antibody-drug conjugates, to give them their full name, are all the rage among the world’s biggest drugmakers. Pfizer is paying $43bn for Seagen, which in turn has just teamed up
→ Continue reading at The Economist
